SEC Form 424B4 filed by Jyong Biotech Ltd.
$MENS
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech") notes the recent fluctuation in its share price and the increased trading volume of its shares on the Nasdaq Stock Exchange following the expiry of the lock-up period this month. The Company has been in ongoing discussions with certain investment funds that are interested in purchasing the Company's ordinary shares. The Company confirms that it is in compliance with its continuous disclosure obligations under the SEC regulations. The Company is not aware of any material, unpublished price-sensitive information or corporate developments that would explain the recen
New Taipei City, Taiwan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that it has entered into a non-binding Memorandum of Understanding (the "MOU") with a Vietnam‑based pharmaceutical distribution company headquartered in Ho Chi Minh City, to evaluate the development and commercialization of MCS‑2 in the Vietnam pharmaceutical market.
New Taipei City, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that the Company has entered into a non‑binding letter of intent (the "LOI") with a South Korean pharmaceutical company to review and evaluate the potential in‑licensing and development of Jyong Biotech's plant-derived new drug MCS-2for the Korean market. The prospec
SP 15D2 - Jyong Biotech Ltd. (0001954488) (Filer)
424B4 - Jyong Biotech Ltd. (0001954488) (Filer)